Sandra Sanders-van Wijk
Polygenic Score for Beta-Blocker Survival Benefit in European Ancestry Patients with Reduced Ejection Fraction Heart Failure
Lanfear D, Li J, Brunner-La Rocca H, Kraus W, Sabbah H, Maeder M, Zeld N, Sanders-van Wijk S, Adams K, O'Connor C, Donahue M, Gui H, She R, Luzum J, Williams L. Polygenic Score for Beta-Blocker Survival Benefit in European Ancestry Patients with Reduced Ejection Fraction Heart Failure. Circ Heart Fail 2020
04.10.2020Polygenic Score for Beta-Blocker Survival Benefit in European Ancestry Patients with Reduced Ejection Fraction Heart Failure
04.10.2020Circ Heart Fail 2020
Lanfear David E, Li Jia, Brunner-La Rocca Hans-Peter, Kraus William E, Sabbah Hani N, Maeder Micha, Zeld Nicole, Sanders-van Wijk Sandra, Adams Kirkwood F, O'Connor Christopher M, Donahue Mark P, Gui Hongsheng, She Ruicong, Luzum Jasmine A, Williams L Keoki
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial
Stöhr R, Sanders-van Wijk S, Pfisterer M, Jeker U, Schuh A, Leibundgut G, Maeder M, Heine G, Brandenburg V, Brunner-La Rocca H. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. Eur J Heart Fail 2020
05.02.2020Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial
05.02.2020Eur J Heart Fail 2020
Stöhr Robert, Sanders-van Wijk Sandra, Pfisterer Matthias, Jeker Urs, Schuh Alexander, Leibundgut Gregor, Maeder Micha, Heine Gunnar H, Brandenburg Vincent M, Brunner-La Rocca Hans-Peter
Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine
Davarzani N, Brunner-La Rocca H, Peeters R, Pfisterer M, Zaugg C, Rolny V, Block D, de Boer R, Suter T, Karel J, Smirnov E, Rickenbacher P, Maeder M, Sanders-van Wijk S, TIME-CHF Investigators. Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine. EPMA J 2018; 9:161-173.
13.05.2018Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine
13.05.2018EPMA J 2018; 9:161-173
Davarzani Nasser, Brunner-La Rocca Hans-Peter, Peeters Ralf, Pfisterer Matthias E, Zaugg Christian, Rolny Vinzent, Block Dirk, de Boer Rudolf A, Suter Thomas, Karel Joël, Smirnov Evgueni, Rickenbacher Peter, Maeder Micha, Sanders-van Wijk Sandra, TIME-CHF Investigators
N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF
Davarzani N, Peeters R, Rickenbacher P, Pfisterer M, Gutmann M, Leibundgut G, Maeder M, Karel J, Sanders-van Wijk S, Brunner-La Rocca H. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. J Card Fail 2017; 23:382-389.
13.02.2017N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF
13.02.2017J Card Fail 2017; 23:382-389
Davarzani Nasser, Peeters Ralf, Rickenbacher Peter, Pfisterer Matthias E, Gutmann Marc, Leibundgut Gregor, Maeder Micha, Karel Joël, Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF
Sanders-van Wijk S, Brunner-La Roccaenen H, Latini R, Rickli H, Tobler D, Tavazzi L, Gorini M, Rickenbacher P, Milani V, Masson S. Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF. Clin Chem 2016; 62:605-16.
02.03.2016Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF
02.03.2016Clin Chem 2016; 62:605-16
Sanders-van Wijk Sandra, Brunner-La Roccaenen Hans-Peter, Latini Roberto, Rickli Hans, Tobler Daniel, Tavazzi Luigi T, Gorini Marco, Rickenbacher Peter, Milani Valentina, Masson Serge
Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF
Zurek M, Brunner-La Rocca H, Pfisterer M, Jeker U, Handschin R, Abbühl H, Sanders-van Wijk S, Muzzarelli S, Rickli H, Maeder M, TIME-CHF Investigators. Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF. J Card Fail 2015
07.01.2015Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF
07.01.2015J Card Fail 2015
Zurek Marzena, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Jeker Urs, Handschin Rolf, Abbühl Heidi, Sanders-van Wijk Sandra, Muzzarelli Stefano, Rickli Hans, Maeder Micha, TIME-CHF Investigators
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF
Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, Nietlispach F, Maeder M, TIME-CHF Investigators. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail 2013; 7:131-9.
18.12.2013Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF
18.12.2013Circ Heart Fail 2013; 7:131-9
Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter, Pfisterer Matthias P, Peter Martin, Rickenbacher Peter, Erne Paul, Estlinbaum Werner, Rickli Hans, Nietlispach Fabian, Maeder Micha, TIME-CHF Investigators
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)
Sanders-van Wijk S, Brunner-La Rocca H, Pfisterer M, Peter M, Vuillomenet A, Rickenbacher P, Erne P, Estlinbaum W, Rickli H, van Asselt A, TIME-CHF Investigators. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart Fail 2013; 1:64-71.
04.02.2013Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)
04.02.2013JACC Heart Fail 2013; 1:64-71
Sanders-van Wijk Sandra, Brunner-La Rocca Hans-Peter, Pfisterer Matthias E, Peter Martin, Vuillomenet André, Rickenbacher Peter, Erne Paul, Estlinbaum Werner, Rickli Hans, van Asselt Antoinette D I, TIME-CHF Investigators